IMS Health, which provides healthcare data and consulting services to drug makers, payers and healthcare providers, announced terms for its IPO on Monday. The Danbury, CT-based company plans to raise approximately $1.27 billion by offering 65 million shares (20% insider) at a price range of $18 to $21. At the midpoint of the proposed range, IMS Health would command a fully diluted market value of $6.7 billion. IMS Health, which was founded in 1954 and booked $2.5 billion in sales for the fiscal year ended December 31, 2013, plans to list on the NYSE under the symbol IMS. J.P. Morgan, Goldman Sachs, Morgan Stanley, BofA Merrill Lynch, Barclays, Deutsche Bank and Wells Fargo are the joint bookrunners on the deal.
